



# SAXOCELL<sup>®</sup>

## CONFERENCE 2026

June 2 - 3, 2026 | Dresden



### Programme

#### When

Tuesday, June 2<sup>nd</sup> to Wednesday, June 3<sup>rd</sup>, 2026

June 2<sup>nd</sup> – Welcome reception, Start at 6 pm

June 3<sup>rd</sup> – Start at 9 am, End approx. 6 pm

#### Location Venue

[Penck Hotel Dresden, Ostra-Allee 33, 01067 Dresden](#)

#### June 2<sup>nd</sup>

| Time                  |  |
|-----------------------|--|
| 5.15 pm               | Registration   |
| 6.00 – 6.30 pm        | Welcome Address  |
|                       | Welcome by the moderator Isabel Werdin   |
|                       | A welcome from BMFTR <ul style="list-style-type: none"> <li>• Dr. Ralf Gebel (Head of the sub-department “Innovative Ecosystems” at the BMFTR)</li> </ul>  |
|                       | A welcome from Saxony <ul style="list-style-type: none"> <li>• Alexander Dierks (President of the Saxon State Parliament)</li> <li>• Prof. Dr. Heike Graßmann (State Secretary at the SMWK)</li> </ul> |
| 6.30 pm               | <a href="#">Opening of the dinner buffet</a>   |
| <b>7.00 – 8.30 pm</b> | <b>Dinner Key Notes</b>  |
|                       | <b>Lorenz Mayr</b> , <i>Future Vision and Trends in Cell and Gene Therapy</i>  |
|                       | <b>Verena Lütschg</b> , Technology on the rise: Innovation requires enthusiasm   |
| <b>9.00 – 9.10 pm</b> | <b>Felix Lansing</b> , SaxoCell Innovation Spotlight – Seamless Therapeutics   |
| End at 10 pm          | <a href="#">Get-together</a>   |

#### June 3<sup>rd</sup>

| Time                  |  |
|-----------------------|--|
| <b>8.15 am</b>        | Registration & coffee  |
| <b>9.00 – 9.15 am</b> | Welcome by the SaxoCell speakers<br><b>Ulrike Köhl</b> and <b>Frank Buchholz</b> |



|                         |   |
|-------------------------|---|
| <b>9.15 – 10.30 am</b>  | <b>Session 1: Cell and Gene therapy in oncology</b>   |
|                         | <b>Marcela V. Maus</b> , New insights into CAR T cells  |
|                         | <b>Katrin Wetzko</b> , TCRs/TILs in solid tumors - state of the art   |
|                         | <b>Ulrike Weirauch</b> , Digital Molecular Medicine Approaches for Immunomonitoring Strategy Development and Improvement of Patient Care in Engineered Adoptive Cell Therapy                    |
|                         | <b>Xiaohan Liang</b> , Optimizing Cell and Gene Therapy Workflows with High-Performance Proteins and Antibodies   |
|                         | Coffee Break  |
| <b>10.50 – 11.50 am</b> | <b>Session 2: Cell and Gene therapy in autoimmune diseases and degeneration</b>   |
|                         | <b>Dimitrios Mouggiakakos</b> , CAR T cells in autoimmune diseases  |
|                         | <b>Fabian Müller</b> , CD19 CAR T cells in autoimmune disease - from deep B cell depletion to lasting remission   |
|                         | <b>Mike Karl</b> , Human preclinical modeling of cell therapies for vision loss   |
|                         | Lunch Break & Poster session  |
| <b>12.50 – 1.15 pm</b>  | <b>Pitch sessions for pre-seeds and start-ups</b>   |
|                         | TQ Therapeutics, <b>Christin Zündorf</b>  |
|                         | NanoVation Therapeutics, <b>Dominik Witzigmann</b>  |
|                         | Cancelico, <b>Jan Moritz Middeke</b>  |
|                         | BioThrust, <b>Patrick Bongartz</b>  |
|                         | Green Elephant Biotech, <b>Katharina Günther</b>  |
|                         | SMART-NK Therapeutics, <b>Jiri Eitler</b>   |
|                         | Coffee Break  |
| <b>1.40 – 2.50 pm</b>   | <b>Session 3: Delivery Technologies and new trends in Genetic Engineering</b>   |
|                         | <b>Kathrin Schumann</b> , Strategies for Safer CRISPR-Engineering of Human T Cells  |
|                         | <b>Ernst Wagner</b> , Chamaeleon Nanocarriers for RNA Delivery and Genome Editing   |
|                         | <b>Julian Jude</b> , Writing The Future - From DNA to Ai  |
|                         | <b>Martin Rabel</b> , A next-generation ionizable lipid LNP platform enabling efficient in vivo CAR T cell generation in mice and NHP using passive and active immune cell targeting strategies |
|                         | Coffee Break  |



# SA<sup>X</sup>OC<sup>ELL</sup>® CONFERENCE 2026

June 2 - 3, 2026 | Dresden



|                       |  |
|-----------------------|--|
| <b>3.20 – 5.40 pm</b> | <b>Session 4: Challenges towards clinical translation and financing</b>  |
|                       | <b>Marcelina Bugaj</b> , The Therapy Begins Before the Infusion: A Patient Perspective on Anti-CD19 CAR-T Cell Therapy in ACPA-Positive Rheumatoid Arthritis |
|                       | <b>Christoph Conrad</b> , Regulation as a Compass – Learnings from Two Years of Supporting Academic Translation  |
|                       | <b>Rebekka Wehner</b> , Clinical relevance of multiplex IHC-based characterization of the tumor immune landscape   |
|                       | <b>Andreas Traube</b> , From craft to scale - Matrix Manufacturing for Cost-Efficient Cell and Gene Therapy Production                                       |
|                       | <b>Tomasz Baran</b> , Perinatal Stem Cell Banking as a Platform for ATMP Development   |
|                       | <b>Ion Tcacencu</b> , Regulatory Roadmaps to Translate Academic ATMP Innovations into Clinic   |
|                       | <b>Panel Discussion</b> „How to Overcome the Valley of Death in CGT Development?“ – Martin Bornhäuser, Regina Demlová, Ralf Huss, Marion Jung                |
| <b>5.40 – 6.00 pm</b> | <b>Poster and Pitch Award ceremony &amp; Closing remarks</b>   |
| <b>6.00 – 8.00 pm</b> | <b>Closing Reception &amp; Networking</b>  |

*Subject to change without notice*